Ribosomal protein L22 like 1: a promising biomarker for lung adenocarcinoma

Wu, Yahua; Yao, Na; Du, Bin; Zhu, Yingjiao; Ji, Xiaohui; Lv, Chengliu; Lai, Jinhuo

doi:10.7150/jca.91759



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2024; 15(9):2549-2560. doi:10.7150/jca.91759 This issue Cite

Research Paper

Ribosomal protein L22 like 1: a promising biomarker for lung adenocarcinoma

Yahua Wu^1#, Na Yao^1#, Bin Du¹, Yingjiao Zhu¹, Xiaohui Ji², Chengliu Lv¹, Jinhuo Lai^1✉

1. Department of Medical Oncology, Fujian Medical University Union Hospital, No. 29 Xinquan Street, Fuzhou, 350000, Fujian, China.
2. Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, 400030, China.
#Yahua Wu and Na Yao contributed equally to this work.

Citation:

Wu Y, Yao N, Du B, Zhu Y, Ji X, Lv C, Lai J. Ribosomal protein L22 like 1: a promising biomarker for lung adenocarcinoma. J Cancer 2024; 15(9):2549-2560. doi:10.7150/jca.91759. https://www.jcancer.org/v15p2549.htm

Other styles

Abstract

No studies have reported the effect of ribosomal protein L22 like 1 (RPL22L1) in lung adenocarcinoma (LUAD). Therefore, we aimed to systematically investigate the role of RPL22L1 in LUAD. The expression of RPL22L1 was analyzed using TCGA, GEO, TIMER, UALCAN databases, and validated by immunohistochemistry (IHC). Gene methylation analysis was performed using the UALCAN, GSCA and MethSurv databases. The immune infiltrates were investigated using the Single Sample Gene Set Enrichment Analysis (ssGSEA), TIMER database, and TISCH database. The results demonstrated that RPL22L1 was up-regulated in LUAD, and verified by IHC. Kaplan-Meier analysis suggested that patients with high RPL22L1 expression had poor prognosis. Multivariate analysis confirmed that RPL22L1 was an independent prognostic factor. Furthermore, RPL22L1 overexpression was associated with hypomethylation, and two CpGs of RPL22L1 were significantly associated with prognosis. Up-regulated RPL22L1 was enriched in MYC targets, E2F targets, G2M checkpoint, mTORC1 signaling, cell cycle, and so on. Moreover, RPL22L1 expression was negatively correlated with immune cell infiltration, and patients with high RPL22L1 expression had lower immune, stromal, and estimate scores. Single-cell analysis suggested that RPL22L1 might have a potential function in the tumor microenvironment (TME) of LUAD. In conclusion, RPL22L1 may be a promising biomarker for LUAD.

Keywords: RPL22L1, Biomarker, Lung adenocarcinoma, Prognosis, TME

Citation styles

APA

Wu, Y., Yao, N., Du, B., Zhu, Y., Ji, X., Lv, C., Lai, J. (2024). Ribosomal protein L22 like 1: a promising biomarker for lung adenocarcinoma. Journal of Cancer, 15(9), 2549-2560. https://doi.org/10.7150/jca.91759.

ACS

Wu, Y.; Yao, N.; Du, B.; Zhu, Y.; Ji, X.; Lv, C.; Lai, J. Ribosomal protein L22 like 1: a promising biomarker for lung adenocarcinoma. J. Cancer 2024, 15 (9), 2549-2560. DOI: 10.7150/jca.91759.

NLM

CSE

Wu Y, Yao N, Du B, Zhu Y, Ji X, Lv C, Lai J. 2024. Ribosomal protein L22 like 1: a promising biomarker for lung adenocarcinoma. J Cancer. 15(9):2549-2560.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.